Myocardial ischemia is characterized by a specific condition, where there is an insufficient flow of blood to the heart muscle (myocardium) through coronary arteries. Due to an obstruction or constriction of the arteries, the heart is not able to pump oxygenated blood and other vital nutrients to the body efficiently and finally leads to destruction of the heart muscles. Blockage of an artery (due to atherosclerotic plaque), blood clots, heart muscle diseases and artery spasms or contraction are few of the causes of myocardial ischemia. Various symptoms of myocardial ischemia include breathlessness, dizziness, heart palpitations, weakness, shoulder pain and chest pain (angina pectoris).
Future Structure and Analysis for Myocardial Ischemia Market: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2959
Based on diagnosis, the myocardial ischemia market can be segmented as follows:
> Cardiac CT scan: Coronary artery clarification can be determined by CT scans and can aid in the diagnosis of coronary atherosclerotic
> Electrocardiogram (ECG) : ECG reveals a heart’s activity with the help of electrodes attached to the patient’s chests, arms and legs
> Nuclear scan: Certain radioactive materials are injected into a patient’s bloodstream and are detected by special cameras as they flow through the blood. Dark spots appear on the scan in those regions where there is limited bloodflow
> Coronary angiography: Coronary angiography uses X-ray imaging to examine to the heart’s internal blood vessels
> Holter monitoring: Holter monitor is a small, portable device which is worn by a patient to record heart rhythm
Based on treatment, the myocardial ischemia can be segmented as follows:
> Angiotensin-converting enzyme (ACE) inhibitors: These inhibitors prevent an enzyme to produce angiotensin II, a substance which affects the cardiovascular system
> Aspirin: Aspirin can reduce the ability of blood clotting, and hence can prevent constriction of coronary arteries
> Beta blockers: Beta blockers control the pace of a patient’s heartbeat, and relaxes the heart muscles
> Nitroglycerine: It improves the blood flow within the body by repairing the arterial blood vessels
> Angioplasty, also referred to as percutaneous coronary intervention (PCI)
> Coronary artery bypass surgery
Based on geography, the myocardial ischemia market can be segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World. Out of these four regions, North America dominates the myocardial ischemia market followed by Europe. The major driving factors for the growth of myocardial ischemia market are increase in the prevalence of various heart-related diseases, and growing awareness of the population about cardiovascular diseases coupled with geriatric population which is rapidly increasing. According to a survey, approximately 1.5 million cases of myocardial ischemia occur annually in the United States. Moreover, technological advancements and increasing competition from small market players have further fueled the growth of myocardial ischemia market. Asia Pacific is developing rapidly and is considered to be as one of the most promising markets for the augmentation of myocardial ischemia market. The factors which will contribute towards the growth of this market in Asia Pacific are presence of emerging economies, constantly changing lifestyles of people which have accelerated the prevalence of serious heart ailments, and better healthcare infrastructures. Furthermore, the increasing need of individuals to opt for the best technology available for their treatment would most probably accentuate the growth of myocardial ischemia market in various Asian countries.
Various pharmaceutical companies are constantly trying to come up with novel therapeutic developments for the treatment of myocardial ischemia. Some of the top major players operating in myocardial ischemia therapeutics market are Baxter International, Inc., Boston Scientific Corporation, Cardium Therapeutics, Inc., ViroMed Co. Ltd., Atrium Medical Corporation, Vasade Biosciences, Inc. and many others.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453